US Bancorp’s Anixa Biosciences ANIX Stock Holding History

US Bancorp’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12K	Hold	400	–	–	﹤0.01%	3956
2026 Q1	$1.03K	Hold	400	–	–	﹤0.01%	3925
2025 Q4	$1.25K	Hold	400	–	–	﹤0.01%	3824
2025 Q3	$1.32K	Hold	400	–	–	﹤0.01%	3800
2025 Q2	$1.32K	Hold	400	–	–	﹤0.01%	3925
2025 Q1	$1.14K	Hold	400	–	–	﹤0.01%	3970
2024 Q4	$928	Hold	400	–	–	﹤0.01%	3965
2024 Q3	$1.26K	Hold	400	–	–	﹤0.01%	3866
2024 Q2	$884	Hold	400	–	–	﹤0.01%	3825
2024 Q1	$1.25K	Hold	400	–	–	﹤0.01%	3793
2023 Q4	$1.55K	Hold	400	–	–	﹤0.01%	3741
2023 Q3	$1.31K	Hold	400	–	–	﹤0.01%	3727
2023 Q2	$1.28K	Hold	400	–	–	﹤0.01%	3778
2023 Q1	$1.72K	Hold	400	–	–	﹤0.01%	3790
2022 Q4	$1.7K	Hold	400	–	–	﹤0.01%	3816
2022 Q3	$2K	Hold	400	–	–	﹤0.01%	3795
2022 Q2	$1K	Sell	400 -13,249	-97%	-$41.8K	﹤0.01%	3923
2022 Q1	$37K	Buy	13,649 +13,249	+3,312%	+$38.9K	﹤0.01%	2767
2021 Q4	$1K	Buy	+400	New	+$1.62K	﹤0.01%	3957

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

US Bancorp's ANIX Position: Q2 2026 in Review

US Bancorp held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 400 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #3956.

US Bancorp first reported a position in ANIX in Q4 2021 and has held it in 19 quarters since. The position peaked at $37K in Q1 2022. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

US Bancorp held 400 shares of Anixa Biosciences worth $1.12K as of Q2 2026.
US Bancorp left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3956 holding.
US Bancorp first reported a position in Anixa Biosciences in Q4 2021 and has held it in 19 quarters since.
US Bancorp's Anixa Biosciences position peaked at $37K in Q1 2022.
63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.